诺泰生物(688076) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for the reporting period was ¥355,815,137.72, representing a year-on-year increase of 71.02%[3] - The net profit attributable to shareholders of the listed company was ¥66,326,817.02, reflecting a significant increase of 215.65% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥65,398,489.22, which is an increase of 179.69% year-on-year[3] - The basic earnings per share were ¥0.31, an increase of 210.00% year-on-year[4] - The diluted earnings per share were ¥0.30, reflecting a year-on-year increase of 200.00%[4] - The company reported a total profit for the current period of $80,450,710.62, significantly higher than $23,528,055.19 in the previous period, indicating strong performance[60] - Net profit attributable to shareholders of the parent company reached $66,326,817.02, up from $21,012,921.56 in the previous period, showing substantial growth[60] - Operating profit for the current period was $80,820,160.49, compared to $29,113,137.96 in the previous period, indicating improved operational efficiency[60] Research and Development - The total R&D investment amounted to ¥67,160,727.44, marking a substantial increase of 221.59% compared to the previous year[4] - R&D investment accounted for 18.88% of operating revenue, up by 8.84 percentage points from the previous year[4] - Research and development expenses surged to ¥66,247,412.85 in Q1 2024, compared to ¥20,040,929.04 in Q1 2023, reflecting a growth of approximately 230.5%[27] Cash Flow and Assets - The net cash flow from operating activities was ¥78,484,262.52, showing a decrease of 45.77% compared to the previous year[4] - Net cash flow from operating activities for Q1 2024 was ¥78,484,262.52, down from ¥144,720,177.89 in Q1 2023[31] - Total assets at the end of the reporting period were ¥3,719,260,681.86, an increase of 4.85% from the end of the previous year[4] - Total assets increased to ¥3,719,260,681.86 in Q1 2024, compared to ¥3,547,245,952.44 in Q1 2023, marking a growth of about 4.8%[27] - Cash inflow from investment activities in Q1 2024 was ¥260,262,153.82, compared to ¥106,461,541.49 in Q1 2023, indicating a significant increase of approximately 144.4%[31] - Cash and cash equivalents as of March 31, 2024, amount to ¥498,518,585.31, a decrease from ¥677,532,732.81 at the beginning of the period[56] Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,974[42] - The largest shareholder, Lianyungang Nuotai Investment Management Partnership, holds 20,000,000 shares, accounting for 9.38% of total shares[42] - The company's total equity attributable to shareholders increased to ¥2,250,061,830.38 in Q1 2024 from ¥2,170,268,338.07 in Q1 2023, reflecting a growth of about 3.7%[27] Liabilities and Financing - The company's total liabilities reached ¥1,450,905,500.48 in Q1 2024, up from ¥1,357,942,277.69 in Q1 2023, indicating an increase of approximately 6.8%[27] - Total liabilities as of March 31, 2024, are ¥1,450,906,500.96, compared to ¥1,357,942,277.69 at the end of 2023[50] - The company raised ¥260,000,000.00 through borrowings in Q1 2024, up from ¥155,000,000.00 in Q1 2023[56] - The net cash flow from financing activities in Q1 2024 is ¥148,481,151.48, compared to ¥95,763,478.78 in Q1 2023[56] Other Financial Metrics - The company reported a credit impairment loss of $-3,559,938.47, contrasting with a gain of $3,349,016.38 in the previous period, highlighting a shift in asset quality[60] - The company experienced a fair value change loss of $-359,504.49, which was not present in the previous period, suggesting market volatility impacts[60] - The company did not report any net profit from the merged entity prior to the merger, consistent with the previous period[61] - The company is not applying new accounting standards for the current reporting period, maintaining consistency in financial reporting[64] - The total income from other gains increased to $3,267,875.41 from $2,778,268.93, reflecting enhanced revenue streams[60] - The company reported a decrease in operating expenses, with a significant drop from $5,752,889.22 to $439,183.07, indicating cost control measures[60]